Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Trajectories of symptom severity predicts quality of life change in newly diagnosis lymphoma survivors: An initial study

Trajectories of symptom severity predicts quality of life change in newly diagnosis lymphoma... INTRODUCTIONLymphoma is the leading hematologic malignancy. Non‐Hodgkin lymphomas (NHL) comprise a wide variety of neoplasms arising from the lymphoid tissues. With an estimated 544,352 new cases and 259,793 deaths in 2020, lymphoma accounts for approximately 3% of all cancers worldwide (Sung et al., 2021). Advancements in treatment have resulted in a growing number of cancer survivors enjoying longer lifespans. During the last decade, the 5‐year relative survival rate was 73.2% for lymphoma (NCI, 2021). Unlike solid tumours, lymphoma can only be relieved and cured by chemotherapy. Although lymphoma has a higher rate of treatment success and survival than other types of cancer, its attributes are closely intertwined with the immunological functions of the body. Chemotherapy and its subsequent side effects result in lymphoma consuming more medical resources than other types of cancer. According to the National Health Insurance Administration Ministry of Health and Welfare's data (2020) on medical expenses from the National Health Insurance on malignant neoplasms, lymphoma incurs an average medical cost of NT$246,780 per patient, fourth only to leukaemia, oesophageal cancer and lung cancer in Taiwan. The short‐ or long‐term side effects of treatment include unpleasant experiences and mental and physical disturbances, which continue to undermine survivors' quality of life http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

Trajectories of symptom severity predicts quality of life change in newly diagnosis lymphoma survivors: An initial study

Download PDF
11 pages

Loading next page...
 
/lp/wiley/trajectories-of-symptom-severity-predicts-quality-of-life-change-in-Hfj0D4kwm4
Publisher
Wiley
Copyright
© 2022 John Wiley & Sons Ltd
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/ecc.13741
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONLymphoma is the leading hematologic malignancy. Non‐Hodgkin lymphomas (NHL) comprise a wide variety of neoplasms arising from the lymphoid tissues. With an estimated 544,352 new cases and 259,793 deaths in 2020, lymphoma accounts for approximately 3% of all cancers worldwide (Sung et al., 2021). Advancements in treatment have resulted in a growing number of cancer survivors enjoying longer lifespans. During the last decade, the 5‐year relative survival rate was 73.2% for lymphoma (NCI, 2021). Unlike solid tumours, lymphoma can only be relieved and cured by chemotherapy. Although lymphoma has a higher rate of treatment success and survival than other types of cancer, its attributes are closely intertwined with the immunological functions of the body. Chemotherapy and its subsequent side effects result in lymphoma consuming more medical resources than other types of cancer. According to the National Health Insurance Administration Ministry of Health and Welfare's data (2020) on medical expenses from the National Health Insurance on malignant neoplasms, lymphoma incurs an average medical cost of NT$246,780 per patient, fourth only to leukaemia, oesophageal cancer and lung cancer in Taiwan. The short‐ or long‐term side effects of treatment include unpleasant experiences and mental and physical disturbances, which continue to undermine survivors' quality of life

Journal

European Journal of Cancer Care – Wiley

Published: Nov 1, 2022

Keywords: lymphoma survivors; predominant symptoms; quality of life; trajectories of symptom severity

References

  • Cancer‐related psychological distress in lymphoma survivor: An Italian cross‐sectional study
    Agostinelli, G.; Muzzatti, B.; Serpentini, S.; Spina, M.; Annunziata, M. A.
  • Quality of life in older survivors of non‐Hodgkin's lymphoma who received chemotherapy and related factors
    Ariestine, D. A.; Sari, N. K.; Rinaldi, I.; Abdullah, M.
  • Symptoms experience: a concept analysis
    Armstrong, T. S.
  • Insomnia and Fatigue Symptom Trajectories in Breast Cancer: A Longitudinal Cohort Study
    Bean, H. R.; Diggens, J.; Ftanou, M.; Weihs, K. L.; Stanton, A. L.; Wiley, J. F.
  • How can I deal with missing data in my study?
    Bennett, D. A.
  • Non‐Hodgkin lymphoma
    Bowzyk Al‐Naeeb, A.; Ajithkumar, T.; Behan, S.; Hodson, D. J.
  • Building dynamic models and theories to advance the science of symptom management research
    Brant, J. M.; Beck, S.; Miaskowski, C.
  • Symptom trajectories during chemotherapy in outpatients with lung cancer colorectal cancer, or lymphoma
    Brant, J. M.; Beck, S. L.; Dudley, W. N.; Cobb, P.; Pepper, G.; Miaskowski, C.
  • Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
    Cella, D.; Bushmakin, A. G.; Cappelleri, J. C.; Charbonneau, C.; Michaelson, M. D.; Motzer, R. J.
  • Development of a measure of health‐related quality of life for non‐Hodgkin's lymphoma clinical research: The functional assessment of cancer therapy lymphoma (FACT‐ Lym)
    Cella, D.; Webster, D.; Cashy, J.; Katikova, L.; Burgess, M. F.; Lin, B. K.
  • Cancer pain and lower functional status predict poor trajectories of symptom and fatigue distress in patients with lung cancer
    Chien, T. W.; Lai, C. Y.; Huang, S. S.; Tsai, L. Y.; Tsai, M. C.; Tsay, S. L.
  • Improving Provision of Care for Long‐term Survivors of Lymphoma
    Ciavarella, S.; Minoia, C.; Quinto, A. M.; Oliva, S.; Carbonara, S.; Cormio, C.; Cox, M. C.; Bravo, E.; Santoro, F.; Napolitano, M.; Spina, M.; Loseto, G.; Guarini, A.
  • A power primer
    Cohen, J.
  • Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy
    Dirksen, S. R.; Belyea, M. J.; Wong, W.; Epstein, D. R.
  • Associations between cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression in patients prior to breast cancer surgery
    Doong, S. H.; Dhruva, A.; Dunn, L. B.; West, C.; Paul, S. M.; Cooper, B. A.; Elboim, C.; Abrams, G.; Merriman, J. D.; Langford, D. J.; Leutwyler, H.; Baggott, C.; Kober, K.; Aouizerat, B. E.; Miaskowski, C.
  • Self‐reported quality of life in elderly patients with aggressive non‐Hodgkin's lymphoma treated with CHOP chemotherapy
    Doorduijn, J.; Buijt, I.; Holt, B.; Steijaert, M.; Uyl‐de Groot, C.; Sonneveld, P.
  • # 1124/Development and multilingual validation of the Fact‐Lymphoma instrument
    Eremenco, S.; Webster, K.; Kutikova, L.; Bowman, L.; Cella, D.
  • Symptom clusters in young and middle‐aged lymphoma patients receiving chemotherapy
    Feng, L. N.; Feng, L. X.; Meng, L.
  • Prevention of granulocyte‐colony stimulating factor (G‐CSF) induced bone pain using double histamine blockade
    Gavioli, E.; Abrams, M.
  • EORTC QLQ‐C30 and FACT‐Lym for the assessment of health‐related quality of life of newly diagnosed lymphoma patients undergoing chemotherapy
    Georgakopoulos, A.; Kontodimopoulos, N.; Chatziioannou, S.; Niakas, D.
  • The Hawthorne effect in direct observation research with physicians and patients
    Goodwin, M. A.; Stange, K. C.; Zyzanski, S. J.; Crabtree, B. F.; Borawski, E. A.; Flocke, S. A.
  • The development and validation of a measure of health‐related quality of life for non‐Hodgkin's lymphoma: The functional assessment of cancer therapy—Lymphoma (FACT‐Lym)
    Hlubocky, F. J.; Webster, K.; Cashy, J.; Beaumont, J.; Cella, D.
  • Symptom clusters in childhood cancer survivors in Korea: A latent class analysis
    Hong, H. C.; Kim, Y. M.; Min, A.
  • Symptom clusters in ovarian cancer patients with chemotherapy after surgery: A longitudinal survey
    Huang, J.; Gu, L.; Zhang, L.; Lu, X.; Zhuang, W.; Yang, Y.
  • Future cancer research priorities in the USA: a Lancet Oncology Commission
    Jaffee, E. M.; Dang, C. V.; Agus, D. B.; Alexander, B. M.; Anderson, K. C.; Ashworth, A.; Barker, A. D.; Bastani, R.; Bhatia, S.; Bluestone, J. A.; Brawley, O.; Butte, A. J.; Coit, D. G.; Davidson, N. E.; Davis, M.; DePinho, R. A.; Diasio, R. B.; Draetta, G.; Frazier, A. L.; Yung, A.
  • Health‐related quality of life in non‐Hodgkin lymphoma survivors: A prospective cohort study
    Kang, D.; Cho, J.; Kim, I. R.; Kim, M. K.; Kim, W. S.; Kim, S. J.
  • Cancer symptom cluster management
    Kwekkeboom, K. L.
  • Symptom clusters in breast cancer survivors: A latent class profile analysis
    Lee, L.; Ross, A.; Griffith, K.; Jensen, R. E.; Wallen, G. R.
  • Patient‐reported long‐term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B‐cell lymphoma
    Maziarz, R. T.; Waller, E. K.; Jaeger, U.; Fleury, I.; McGuirk, J.; Holte, H.; Jaglowski, S.; Schuster, S. J.; Bishop, M. R.; Westin, J. R.; Mielke, S.; Teshima, T.; Bachanova, V.; Foley, S. R.; Borchmann, P.; Salles, G. A.; Zhang, J.; Tiwari, R.; Pacaud, L. B.; Tam, C. S.
  • The relationship between pain, fatigue, sleep disorders and quality of life in adult patients with acute leukaemia: During the first year after diagnosis
    Miladinia, M.; Baraz, S.; Ramezani, M.; Malehi, A. S.
  • The Karnofsky performance status scale: An examination of its reliability and validity in a research setting
    Mor, V.; Laliberte, L.; Morris, J. N.; Wiemann, M.
  • Group‐based trajectory modeling in clinical research
    Nagin, D. S.; Odgers, C. L.
  • Predicting health‐related quality of life in cancer patients receiving chemotherapy: a structural equation approach using the self‐control model
    Park, Y. R.; Park, E. Y.; Kim, J. H.
  • Symptom clusters and related factors in bladder cancer patients three months after radical cystectomy
    Ren, H.; Tang, P.; Zhao, Q.; Ren, G.
  • Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: Results from a two‐stage, phase IB study
    Salar, A.; Avivi, I.; Bittner, B.; Bouabdallah, R.; Brewster, M.; Catalani, O.; Follows, G.; Haynes, A.; Hourcade‐Potelleret, F.; Janikova, A.; Larouche, J. F.; McIntyre, C.; Pedersen, M.; Pereira, J.; Sayyed, P.; Shpilberg, O.; Tumyan, G.
  • Symptom clustering and its effect on functional status in lymphoma patients
    Sezgin, M. G.; Bektas, H.
  • Prevalence of symptoms, with a focus on fatigue, and changes of symptoms over three months in outpatients receiving cancer chemotherapy
    Spichiger, E.; Muller‐Frohlich, C.; Denhaerynck, K.; Stoll, H.; Hantikainen, V.; Dodd, M.
  • Using group‐based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non‐surgical therapy
    Shi, Q.; Mendoza, T. R.; Gunn, G. B.; Wang, X. S.; Rosenthal, D. I.; Cleeland, C. S.
  • Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
    Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F.
  • Health‐related quality‐of‐life outcomes in patients with classical Hodgkin lymphoma: A prospective, observational study in us oncology practices
    Svoboda, J.; Armand, P.; Taylor, F.; Sun, X.; Moreno‐Koehler, A.; Gajavelli, S.; Peterson, D.; Chen, C.
  • Symptom clusters and quality of life in China patients with lung cancer undergoing chemotherapy
    Wang, D.; Fu, J.
  • A review of the literature on symptom clusters in studies that included oncology patients receiving primary or adjuvant chemotherapy
    Ward Sullivan, C.; Leutwyler, H.; Dunn, L. B.; Miaskowski, C.
  • Validity and reliability study on traditional Chinese FACT‐C in Chinese patients with colorectal neoplasm
    Wong, C. K.; Lam, C. L.; Law, W. L.; Poon, J. T.; Chan, P.; Kwong, D. L.; Tsang, J.
  • The Functional Assessment of Cancer Therapy–General (FACT‐G) is valid for monitoring quality of life in patients with non‐Hodgkin lymphoma
    Yost, K. J.; Thompson, C. A.; Eton, D. T.; Allmer, C.; Ehlers, S. L.; Habermann, T. M.; Shanafelt, T. D.; Maurer, M. J.; Slager, S. L.; Link, B. K.; Cerhan, J. R.